Pivotal clinical trials in C3 glomerulopathy: answers and remaining uncertainties
Nephrology Dialysis Transplantation · 03.07.2026
DOI: 10.1093/ndt/gfag155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 03.07.2026. Verfasst von Fernando Caravaca-Fontan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, European Union.
Abstract (Originalsprache)
Complement 3 glomerulopathy (C3G) and primary immune complex–mediated membranoproliferative glomerulonephritis (IC-MPGN) are ultra-rare glomerular diseases driven by dysregulation of the complement system, most commonly involving the alternative pathway. Recent advances in the understanding of disease pathogenesis have enabled the development of targeted complement therapies. The publication of pivotal phase 3 trials evaluating proximal complement inhibitors—iptacopan, a selective factor B inhibitor, and pegcetacoplan, a C3 inhibitor—marks a turning point in the management of C3G and IC-MPGN. Both agents demonstrated clinically meaningful reductions in proteinuria and stabilization of kidney function, establishing proof of efficacy. Despite these advances, important uncertainties remain. Key unresolved issues include optimal patient selection, timing and duration of therapy, treatment sequencing, monitoring strategies, and long-term kidney outcomes. Conventional immunosuppressive approaches provide inconsistent benefit and do not directly address complement dysregulation, while validated biomarkers to guide complement blockade are lacking. Additional challenges relate to treatment discontinuation, management of special populations, and health-system implementation. This review critically appraises the evidence from recent pivotal trials, highlighting both their transformative impact and the questions they raise. We emphasize the need for long-term outcome studies, precision-based therapeutic strategies, and pragmatic real-world data. Ultimately, the challenge ahead is not whether complement inhibition is effective but how best to deploy these therapies to maximize durable benefit, minimize risk, and ensure equitable access.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
- Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden.
- Cork University Hospital, University College Cork, Cork, Republic of Ireland.
- Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University of Munich, Munich, Germany.
- Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK.
ORCID-Profile: Fernando Caravaca-Fontan, Stefanie Steiger, Kate I Stevens, Y K Onno Teng, Safak Mirioglu, Luis F Quintana
Förderung
- Instituto de Salud Carlos III
- European Union
Zitieren
APA
Caravaca-Fontan, F., Bruchfeld, A., Moran, S. M., Steiger, S., Stevens, K. I., Teng, Y. K. O., Frangou, E., Mirioglu, S., Quintana, L. F., & Kronbichler, A. (2026). Pivotal clinical trials in C3 glomerulopathy: answers and remaining uncertainties. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag155
Vancouver
Caravaca-Fontan F, Bruchfeld A, Moran SM, Steiger S, Stevens KI, Teng YKO, et al. Pivotal clinical trials in C3 glomerulopathy: answers and remaining uncertainties. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag155
BibTeX
@article{CaravacaFontan2026,
author = {Caravaca-Fontan, Fernando and Bruchfeld, Annette and Moran, Sarah M and Steiger, Stefanie and Stevens, Kate I and Teng, Y K Onno and Frangou, Eleni and Mirioglu, Safak and Quintana, Luis F and Kronbichler, Andreas},
title = {Pivotal clinical trials in C3 glomerulopathy: answers and remaining uncertainties},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag155}
}
EUVIMED